These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 22358352)

  • 1. Durability of the first combined antiretroviral regimen in patients with AIDS at a reference center in Belo Horizonte, Brazil, from 1996 to 2005.
    Ribeiro FA; Tupinambás U; Fonseca MO; Greco DB
    Braz J Infect Dis; 2012; 16(1):27-33. PubMed ID: 22358352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study.
    Martin M; Del Cacho E; Codina C; Tuset M; De Lazzari E; Mallolas J; Miró JM; Gatell JM; Ribas J
    AIDS Res Hum Retroviruses; 2008 Oct; 24(10):1263-8. PubMed ID: 18834323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durability of adherence to antiretroviral therapy on initial and subsequent regimens.
    Gardner EM; Burman WJ; Maravi ME; Davidson AJ
    AIDS Patient Care STDS; 2006 Sep; 20(9):628-36. PubMed ID: 16987049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.
    Lima VD; Gill VS; Yip B; Hogg RS; Montaner JS; Harrigan PR
    J Infect Dis; 2008 Jul; 198(1):51-8. PubMed ID: 18498238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors.
    Maggiolo F; Ravasio L; Ripamonti D; Gregis G; Quinzan G; Arici C; Airoldi M; Suter F
    Clin Infect Dis; 2005 Jan; 40(1):158-63. PubMed ID: 15614706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.
    Scherpbier HJ; Bekker V; Pajkrt D; Jurriaans S; Lange JM; Kuijpers TW
    Pediatrics; 2007 Mar; 119(3):e705-15. PubMed ID: 17308244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of pill burden on discontinuation of the initial HAART regimen in minority female patients prescribed 1 pill/day versus any other pill burden.
    Hill S; Kavookjian J; Qian J; Chung A; Vandewaa J
    AIDS Care; 2014; 26(5):595-601. PubMed ID: 24111921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switch to efavirenz (EFV) after protease-inhibitor (PI)-failure: explorative analysis of outcome by baseline viral VS tolerability failure.
    Khaykin P; Postel N; Reeb I; Staszewski S
    Eur J Med Res; 2008 Apr; 13(4):169-72. PubMed ID: 18504172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV.
    Dybul M; Fauci AS; Bartlett JG; Kaplan JE; Pau AK;
    MMWR Recomm Rep; 2002 May; 51(RR-7):1-55. PubMed ID: 12027060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients.
    Cicconi P; Cozzi-Lepri A; Castagna A; Trecarichi EM; Antinori A; Gatti F; Cassola G; Sighinolfi L; Castelli P; d'Arminio Monforte A;
    HIV Med; 2010 Feb; 11(2):104-13. PubMed ID: 19732176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abacavir compared to protease inhibitors as part of HAART regimens for treatment of HIV infection: patient satisfaction and implications for adherence.
    Jordan J; Cahn P; Goebel F; Matheron S; Bradley C; Woodcock A
    AIDS Patient Care STDS; 2005 Jan; 19(1):9-18. PubMed ID: 15665631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-adherence among patients initiating antiretroviral therapy: a challenge for health professionals in Brazil.
    Bonolo Pde F; César CC; Acúrcio FA; Ceccato Md; de Pádua CA; Alvares J; Campos LN; Carmo RA; Guimarães MD
    AIDS; 2005 Oct; 19 Suppl 4():S5-13. PubMed ID: 16249654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A decade of antiretroviral therapy: a profile of patients with 10 years of highly effective triple therapy].
    Wilson G; Wolff M
    Rev Chilena Infectol; 2012 Jun; 29(3):337-43. PubMed ID: 23096476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reasons and Risk Factors for the Initial Regimen Modification in Chinese Treatment-Naïve Patients with HIV Infection: A Retrospective Cohort Analysis.
    Sun J; Liu L; Shen J; Qi T; Wang Z; Song W; Zhang R; Lu H
    PLoS One; 2015; 10(7):e0133242. PubMed ID: 26207639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of patient beliefs and treatment satisfaction on the discontinuation of current first-line antiretroviral regimens.
    Casado JL; Marín A; Romero V; Bañón S; Moreno A; Perez-Elías MJ; Moreno S; Rodriguez-Sagrado MA
    HIV Med; 2016 Jan; 17(1):46-55. PubMed ID: 26149493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
    Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
    Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies.
    Braithwaite RS; Kozal MJ; Chang CC; Roberts MS; Fultz SL; Goetz MB; Gibert C; Rodriguez-Barradas M; Mole L; Justice AC
    AIDS; 2007 Jul; 21(12):1579-89. PubMed ID: 17630553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.